Direct Acting Antivirals

Direct-acting antivirals (DAAs) are small-molecule medicines designed to inhibit specific viral proteins or enzymes, thereby interrupting viral replication. Their clinical importance is most established in hepatitis C, where short-course oral regimens have transformed treatment by achieving high cure rates across major viral genotypes. The broader category also includes antiviral agents directed at other pathogens, although mechanisms, regulatory pathways, treatment duration, and evidence standards differ substantially by disease.

The market is shaped by public-health priorities, diagnosis and linkage to care, affordability, resistance management, reimbursement, and the ability of health systems to deliver complete treatment courses. Progress therefore depends not only on pharmacological innovation but also on screening, simplified clinical protocols, reliable procurement, and sustained patient access.

The landscape has shifted from specialist-led, highly monitored therapy toward simpler oral treatment pathways. In hepatitis C, the World Health Organization’s 2024 global guidance continues to emphasize simplified, decentralized testing and treatment, including use of non-invasive assessment and pangenotypic regimens where appropriate. This supports delivery in primary-care, community, and harm-reduction settings rather than restricting care to tertiary hospitals.

Generic competition and voluntary licensing have improved affordability in many lower- and middle-income countries, but access remains uneven. Diagnosis is still a major bottleneck: WHO reported that, by the end of 2022, only about one in five people living with hepatitis C had been diagnosed and roughly one in seven had received curative treatment. Elimination progress consequently depends on finding undiagnosed patients, reducing loss between diagnosis and treatment, and maintaining quality-assured supply.

Artificial intelligence can influence DAA delivery through case finding, laboratory interpretation, risk stratification, adherence support, and supply planning. Algorithms can help prioritize people for confirmatory testing, identify patients at risk of treatment interruption, and combine clinical and laboratory data to improve follow-up. In public-health programs, automated data cleaning and dashboards can also reveal gaps across testing, treatment initiation, and cure assessment.

The evidence base is more mature for operational and diagnostic-support applications than for autonomous treatment selection. AI outputs require representative data, external validation, privacy safeguards, and clinician oversight because incomplete records, population bias, and changing resistance patterns can produce unsafe recommendations. The most defensible near-term role is augmenting standardized protocols while preserving confirmatory testing and professional accountability.

North America generally combines advanced diagnostics, specialist expertise, and broad treatment availability with persistent gaps among uninsured, rural, incarcerated, Indigenous, and marginalized populations. Europe benefits from strong regulatory and public-health infrastructure, but national reimbursement, screening policies, and progress toward elimination vary across countries. Asia-Pacific contains both highly capable health systems and large populations facing diagnostic and affordability barriers; decentralized testing and generic access are particularly consequential.

Latin America has expanded access in several settings, yet fragmented procurement, uneven screening, and differences in health-system coverage continue to affect treatment completion. The Middle East faces heterogeneous financing, migration, and surveillance conditions, while conflict and displacement can interrupt continuity of care. Africa carries a substantial burden of viral hepatitis and often needs integrated testing, task sharing, reliable procurement, and treatment models adapted to primary-care capacity. Across all regions, local epidemiology and national guidelines should determine regimen selection and program design.

ASEAN countries face varied disease burdens, regulatory systems, and health-financing arrangements, making regional cooperation on procurement, diagnostics, and supply continuity valuable. BRICS members collectively include major pharmaceutical production and patient populations, but their approaches differ in epidemiology, reimbursement, and domestic manufacturing capacity. The European Union can benefit from coordinated standards and cross-border public-health initiatives, while implementation remains primarily national.

The G7 has substantial research, regulatory, and financing influence and can support elimination programs through technical assistance and resilient supply chains. GCC states generally have comparatively strong health infrastructure and purchasing capacity, but migrant populations and cross-border mobility require inclusive screening and continuity mechanisms. NATO is not a health-market bloc, yet its members’ preparedness, logistics, and health-security cooperation can support continuity of essential medicines during emergencies. These groupings should be viewed as policy and delivery contexts rather than uniform clinical markets.

Australia, Canada, France, Germany, Italy, Spain, the United Kingdom, and the United States have substantial clinical capacity, but case finding among underserved populations remains central to elimination. The United States continues to address disparities linked to incarceration, substance use, insurance, and fragmented care. Canada and Australia have emphasized community-oriented and population-specific approaches, while European countries differ in screening, reimbursement, and national elimination implementation.

Brazil and Mexico must manage large and diverse populations through improvements in diagnosis, decentralized treatment, and procurement efficiency. China and India combine extensive patient populations with major opportunities for domestic manufacturing, simplified pathways, and wider screening; regional variation in access remains important. Japan and South Korea possess advanced health systems, with continued attention to aging populations, surveillance, and equitable access. Russia’s treatment environment is influenced by epidemiology, health-system organization, diagnostics, and continuity of supply. Country-specific conclusions should therefore rely on current national guidelines and verified surveillance rather than assumptions based on income or geography.

Industry leaders should align product strategy with the full care cascade: targeted screening, confirmatory diagnosis, treatment initiation, adherence support, and post-treatment cure assessment. Partnerships with public-health agencies and community providers can improve reach among people who inject drugs, incarcerated populations, migrants, rural communities, and others who are often missed by facility-based models.

Operational priorities include supporting quality-assured generic access where permitted, simplifying packaging and clinical information, strengthening pharmacovigilance, and maintaining diversified supply chains. Organizations developing digital or AI-enabled tools should publish validation results, monitor performance across demographic groups, protect patient data, and retain clinician review. Program performance should be tracked with transparent indicators such as diagnosed proportion, treatment initiation, completion, cure confirmation, reinfection, and equity of coverage.

This executive summary uses a structured review of authoritative public sources, including World Health Organization guidance and surveillance, national health-agency publications, regulatory materials, peer-reviewed clinical and implementation research, and publicly available access and procurement documentation. Evidence was interpreted comparatively across the specified regions, country groups, and countries, with attention to differences in disease burden, diagnosis, treatment policy, reimbursement, and delivery capacity.

Claims were limited to established clinical or public-health findings and deliberately exclude market estimates, market sizing, market shares, forecasts, and company-specific analysis. Because policies, resistance patterns, prices, and program coverage change over time, country-level decisions should be checked against current national guidance, regulatory status, and locally validated epidemiological data.

DAAs have made curative antiviral treatment technically achievable for many people with hepatitis C, but population-level impact remains constrained by undiagnosed infection, uneven access, interrupted care, and reinfection. The strategic opportunity is therefore broader than developing medicines: it is to connect accurate testing with affordable treatment and dependable follow-up.

Leaders that combine evidence-based regimens with decentralized delivery, equitable procurement, responsible digital tools, and measurable public-health outcomes will be best positioned to support elimination goals. Regional and national strategies should remain adaptable, grounded in surveillance, and focused on reaching people who are least likely to enter conventional care.